As elevated TGF-ß levels are a hallmark of severe COVID-19, we were able to additionally demonstrate that ALK5 inhibition also represents a therapy option under conditions with high TGF-ß1 levels [41,78,79]. The gene discussed is TGFBR1; the disease is COVID-19.